vasoactive-intestinal-peptide and Hyperthyroidism

To investigate the underlying mechanisms of Berberine-mediated antidiarrheal effects in thyroid hormone-induced diarrhea in rats, gastrointestinal peptides, such as motilin, gastrin, vasoactive intestinal peptide, and somatostatin from plasma and tissue of hyperthyroid diarrheic rats were measured using radioimmunoassay in healthy control, model, and treated model groups. The number and volume of goblet cells were also observed. Compared with healthy control, hyperthyroid diarrheic rats exhibited a significant reduction in body weight, and increase in plasma concentrations of tri-iodothyronine and free thyroxine along with the increase of wet stool. Both plasma motilin and gastrin were also elevated and reduced remarkably in Berberine-treated subgroup along with the body weight increased and wet stool reduced at the meantime. Significant changes in plasma vasoactive intestinal peptide and somatostatin were not seen. Gastrointestinal peptides trend in tissue samples were similar to those observed in plasma. Morphological data demonstrated an increase in number and/or volume of goblet cells to some extent in duodenum, jejunum, ileum, and colon, respectively and decreased by administration of Berberine. The possible underlying mechanisms of antidiarrheal effects of Berberine may be due in partially to the reduction of the number of goblet cells and the amount of mucous secretion through re-balancing gastrointestinal peptides.

Topics: Animals; Antidiarrheals; Berberine; Colon; Diarrhea; Duodenum; Gastrins; Gastrointestinal Hormones; Goblet Cells; Hyperthyroidism; Jejunum; Male; Motilin; Radioimmunoassay; Rats; Rats, Sprague-Dawley; Somatostatin; Thyroid Hormones; Vasoactive Intestinal Peptide

The effects of transient and sustained hyperthyroidism on vasoactive intestinal polypeptide-like immunoreactivity (VIP-LI) levels were studied in the heart atria of developing and adult rats. Newborn rats were divided into 5 groups. Neo-T animals were treated with thyroxine (T4) during postnatal days 1-8 and sacrificed at the age of 60 days. Neo-S rats were treated with T4 during postnatal days 1-60 and sacrificed one day later. Adult-1 and Adult-2 animals received T4 during days 52-60 and were sacrificed 5-6 days and 1 day later, respectively. Control animals were injected with saline. VIP-LI concentrations were determined in extracts from the left and right atria separately. In Neo-S and Adult-2 rats, spontaneous heart rate, the weight of both atria and total T4 serum levels were significantly enhanced, while their body weight was decreased. The ratio atria weight to body weight was significantly increased in all groups except for Adult-1 animals. Hyperthyroidism led to a significant decrease in VIP-LI levels in both atria of Neo-S and Neo-T rats. Hyperthyroidism induced in adult rats also decreased VIP-LI levels in both atria. However, this change was only transient. In conclusion, our data have provided new evidence that hyperthyroidism induced during the early neonatal period interferes with the development of VIP-ergic innervation in rat atria. The period of the first few postnatal days seems to be essential for this effect, since VIP-LI concentrations in 60-day-old animals did not significantly differ between Neo-S and Neo-T atria.

Topics: Aging; Animals; Female; Heart Atria; Hyperthyroidism; Male; Rats; Rats, Wistar; Vasoactive Intestinal Peptide

Vasoactive intestinal polypeptide (VIP) is a widespread neuropeptide involved in the autonomic nervous control of smooth muscle activity, blood flow and secretion. To study the biosynthetic processing of the VIP precursor in the gut of normal, hypo- and hyperthyroid rats we used antisera against the five functional domains of the precursor molecule, prepro-VIP 22-79, peptide histidine isoleucine (PHI), prepro-VIP 111-122, VIP and prepro-VIP 156-170, to quantify and characterize VIP precursor peptides by radioimmunoassay and chromatography and examine their cellular localization and co-localization by immunohistochemistry. All five peptides were expressed in the gut but not in equimolar amounts as expected from the structure of the VIP precursor. A high concentration of PHV, the C-terminally extended form of PHI which includes prepro-VIP 111-122, was found in the small intestine. Immunohistochemically the prepro-VIP derived peptides were shown to coexist in neuronal elements. Changes in thyroid hormone status induced moderate changes in peptide expression in the gut, the most prominent being a 2-fold increase in all prepro-VIP derived peptides in the gastric fundus of hypothyroid rats. The findings indicate that differences in the post-translational processing of prepro-VIP exist in neurons of the rat gut and that hypo- and hyperthyroidism induce differential changes in peptide expression.

Topics: Animals; Chromatography, Gel; Chromatography, High Pressure Liquid; Colon; Digestive System; Gastric Fundus; Hyperthyroidism; Hypothyroidism; Immune Sera; Immunohistochemistry; Intestine, Small; Male; Protein Precursors; Pyloric Antrum; Radioimmunoassay; Rats; Rats, Sprague-Dawley; Vasoactive Intestinal Peptide

Recent studies have shown that primary hypothyroidism induced in the rat was able to stimulate the biosynthesis of vasoactive intestinal peptide (VIP) in the anterior pituitary (AP). Since the AP VIP is known to stimulate prolactin (PRL) secretion through a paracrine and/or autocrine mechanism, it is interesting to hypothesize that hyperprolactinemia seen in hypothyroid patients may at least in part be due to a paracrine effect of elevated VIP on AP PRL secretion. Prompted by this information, we in the present study examined the effect of VIP load on PRL secretion in patients with primary hyperthyroidism or hypothyroidism, and compared the data with those from thyrotropin-releasing hormone (TRH) load performed in the same patients. Eight female patients with Graves' disease and 8 females with chronic thyroiditis received intravenous bolus injections of VIP (100 micrograms) and TRH (500 micrograms) 2-3 days apart from each other, during both the dysthyroid and euthyroid (attained by medical treatment) states. Compared to the data in the euthyroid state of the respective group, hyperthyroidism was associated with a lower basal PRL level and a lower PRL responsiveness (estimated by net percent increase in PRL) to TRH, whereas hypothyroidism was associated with higher values of these parameters. With respect to VIP, although the peptide was able to significantly stimulate PRL secretion during both the dysthyroid and euthyroid states of hyper- and hypothyroid patients, PRL responsiveness to VIP was essentially the same regardless of thyroid status.(ABSTRACT TRUNCATED AT 250 WORDS)

Topics: Adult; Case-Control Studies; Female; Growth Hormone; Humans; Hyperthyroidism; Hypothyroidism; Middle Aged; Prolactin; Thyrotropin; Thyrotropin-Releasing Hormone; Vasoactive Intestinal Peptide

We report here data on the expression of the various sequences derived from the prepro-vasoactive intestinal polypeptide (VIP) precursor and VIP mRNA in the anterior pituitary gland and cerebral cortex of hypothyroid and hyperthyroid rats. Using specific antisera to each of the prepro-VIP sequences we demonstrated an increase of all prepro-VIP derived sequences, and accordingly, found that the number of cells expressing each of these sequences were markedly augmented in the anterior pituitary of the hypothyroid rats. This was accompanied by a marked increase in VIP mRNA. In the cerebral cortex of the hypothyroid rats no changes were observed. In the pituitary of hyperthyroid animals a significant decrease was seen for prepro-VIP 22-79, VIP and prepro-VIP 156-170, whereas in the cerebral cortex a significant increase was observed for prepro-VIP 22-79, PHI and VIP. We were not able to demonstrate any changes in VIP mRNA in the cerebral cortex or pituitary of the hyperthyroid rats. Gel permeation chromatography and reverse-phase HPLC of extracts from cerebral cortex showed elution profiles identical to the synthetic counterparts. The reported data provide further evidence of a tissue-specific expression and regulation of the VIP gene products.

Topics: Animals; Blotting, Northern; Cerebral Cortex; Chromatography, Gel; Chromatography, High Pressure Liquid; Gene Expression; Hyperthyroidism; Hypothyroidism; Immunohistochemistry; In Situ Hybridization; Male; Pituitary Gland, Anterior; Protein Precursors; Radioimmunoassay; Rats; Rats, Sprague-Dawley; RNA, Messenger; Thyroid Hormones; Vasoactive Intestinal Peptide

A role of thyroid hormone in the regulation of neuropeptide synthesis has been demonstrated in different tissues. In this paper we investigated the vasoactive intestinal peptide (VIP) mRNA expression by means of in situ hybridization in several brain areas of hypo- and hyperthyroid adult rats. Neither hypo- nor hyperthyroidism modified the VIP mRNA levels in the thalamus and in the hypothalamic suprachiasmatic nucleus. In contrast, in the anterior cingulate and frontoparietal motor cortex of hypothyroid rats there was a marked increase in the signal for VIP mRNA per cell, but the number of VIP expressing neurons did not change. These data indicate that also central VIP synthesis can be influenced by the levels of circulating thyroid hormone, but that this effect is confined to specific areas and cell populations of the brain.

Topics: Animals; Brain Chemistry; Cell Count; Gene Expression Regulation; Gyrus Cinguli; Hyperthyroidism; Hypothyroidism; Male; Motor Cortex; Nerve Tissue Proteins; Neurons; Rats; Rats, Sprague-Dawley; RNA, Messenger; Thyroid Hormones; Vasoactive Intestinal Peptide

Plasma levels of the neuropeptides, vasoactive intestinal polypeptide (VIP, neuropeptide Y (NPY), calcitonin gene-related peptide (CGRP), substance P, and galanin were determined in 15 hyperthyroid patients before and at 3 occassions during 38 weeks of treatment. Treatment was performed with either 131I alone or with carbimazole, with combination of carbimazole and thyroxine, or with subtotal thyroidectomy. Before and after 11 (+/- 4), 24 (+/- 6) and 38 (+/- 5) weeks of treatment, plasma neuropeptide levels were analysed. A group of 9 premenopausal women served as controls. During hyperthyroidism, mean plasma level of CGRP was higher than in controls (P less than 0.001). In contrast, the mean plasma levels of the other measured neuropeptides did not differ from those in the controls. Mean serum level of tree T4 was lowered from 81.9 +/- 30.1 to 23.9 +/- 8.6 pmol/l and mean serum level of free T3 was lowered from 27.3 +/- 7.9 to 6.7 +/- 2.3 pmol/l during the course of the treatment. After 11 weeks of treatment, mean plasma NPY level was significantly increased (P = 0.004) compared to pretreatment levels. However, after 38 weeks of treatment, mean plasma NPY level had returned to control values. The mean plasma CGRP level was significantly reduced at 11 and 38 weeks of treatment compared to pre-treatment value (P = 0.002 and P = 0.004, respectively). Mean plasma level of neurotensin slowly declined during the treatment (P = 0.003). In contrast, mean plasma level of VIP, of substance P, and of galanin did not differ from control value before or after treatment.(ABSTRACT TRUNCATED AT 250 WORDS)

Topics: Adult; Aged; Calcitonin Gene-Related Peptide; Carbimazole; Drug Therapy, Combination; Female; Galanin; Humans; Hyperthyroidism; Iodine Radioisotopes; Male; Middle Aged; Neuropeptide Y; Neuropeptides; Peptides; Substance P; Thyroidectomy; Thyroxine; Triiodothyronine; Vasoactive Intestinal Peptide

Long-acting somatostatin analogues such as SMS 201-995 (Sandoz) are being evaluated in a wide range of clinical indications, including gut neuroendocrine tumours and acrogemaly. Long-term continuous SMS 201-995 treatment has achieved useful symptomatic improvement in diarrhoea in 4 patients with metastatic VIPomas who had relapsed following previous treatment. Clinical improvement has outlasted suppression of VIP secretion (suggesting an additional direct antisecretory action of SMS 201-995) and has occurred despite expansion of hepatic metastases. In 6 patients with tumours secreting gastrin and/or glucagon, secretion of these peptides was acutely inhibited by SMS 201-995. However, endocrine and clinical responses to chronic treatment have been less consistent. SMS 201-995 is active orally at doses of 4-8 mg and when given thrice-daily to 6 patients with active acromegaly, suppressed mean 24-h growth hormone levels by 51-88%. Despite significantly reduced plasma insulin concentrations, glucose tolerance did not deteriorate. SMS 201-995 was also effective in suppressing thyroid-stimulating hormone (TSH) and thyroid hormone secretion in a patient with mild thyrotoxicosis due to non-tumoural inappropriate TSH hypersecretion. In all cases SMS 201-995 treatment has been well tolerated and has few side-effects.

Topics: Acromegaly; Adenoma; Adult; Aged; Diarrhea; Female; Gastrointestinal Neoplasms; Glucagonoma; Growth Hormone; Humans; Hyperthyroidism; Liver Neoplasms; Male; Middle Aged; Neoplasms, Glandular and Epithelial; Octreotide; Pancreatic Neoplasms; Pituitary Neoplasms; Somatostatin; Streptozocin; Thyrotropin; Vasoactive Intestinal Peptide; Vipoma; Zollinger-Ellison Syndrome

The effect of changes in thyroid function upon vasoactive intestinal peptide (VIP) induced secretion of saliva were studied in male Wistar rats. Hyperthyroidism was induced by the sc administration every 12 h of 10 micrograms/100 g bw of I-triiodothyronine; hypothyroidism was induced by surgical thyroidectomy 2 weeks before the experiments. Preganglionar parasympathetic denervation was induced by sectioning the chorda tympani on the left side. The dose-response curves to increasing doses of VIP showed in the hypothyroid animals increased salivary secretion, while in the hyperthyroid ones the dose-response to the drug was reduced. This effect was seen on both sides, the denervated and the control ones. In the denervated glands there was a marked hypersensitivity to the administration of VIP producing greater responses with the same doses, in the 3 groups of animals. The negative modulation by thyroid hormones of the salivary response to VIP administration is compared with the positive modulation they induce in the salivary response to beta-adrenergic and cholinergic drugs.

Topics: Animals; Denervation; Dose-Response Relationship, Drug; Hyperthyroidism; Hypothyroidism; Male; Organ Size; Rats; Rats, Inbred Strains; Saliva; Submandibular Gland; Thyroid Hormones; Vasoactive Intestinal Peptide